Casilda Olveira1, Alicia Padilla2, Antonio Dorado3, Victoria Contreras4, Eduardo Garcia-Fuentes4, Elehazara Rubio-Martin4, Nuria Porras4, Esperanza Doña5, Ana Carmona6, Gabriel Olveira4,7. 1. Pneumology Service, IBIMA (Institute of Biomedical Research in Malaga), Regional University of Málaga, Málaga, Spain. 2. Pneumology Unit, The Costa del Sol Health Agency, Málaga, Spain. 3. Pneumology Service, Hospital Regional University of Málaga, Málaga, Spain. 4. Endocrinology and Nutrition Unit, IBIMA (Institute of Biomedical Research in Malaga), Regional University Hospital of Málaga University, Málaga, Spain. 5. Pneumology Unit, High Resolution Hospital of Benalmádena, Málaga, Spain. 6. Department of Medicine and Dermatology, Málaga University Faculty of Medicine, Málaga, Spain. 7. CIBERDEM (CIBER of Diabetes and Associated Metabolic Diseases).
Abstract
OBJECTIVE: In addition to their antibiotic effect, macrolides appear to modulate the inflammatory response in cystic fibrosis (CF) and could influence oxidative stress. The objective of this study was to assess oxidation biomarkers and levels of inflammation and to determine whether there is an association between these parameters and the intake of macrolides. MATERIALS AND METHODS: The subjects included in this cross-sectional study were, on the one hand, clinically stable patients with CF and, on the other, healthy controls. The following serum and plasma inflammatory and oxidative stress biomarkers were measured: interleukin-6 (IL-6), reactive C protein (RCP), tumor necrosis alpha (TNF-α), glutathione peroxidase (GPx), total antioxidant capacity (TAC), catalase (CAT), and superoxide dismutase (SOD), together with markers of lipid peroxidation (8-isoprostanes and thiobarbituric acid reactive substances [TBARS]). Clinical, anthropometric, lung function, radiological, and analytical variables (albumin, prealbumin, vitamins, and zinc) were also recorded. RESULTS: We studied 36 adults with CF and 41 controls. No differences were observed in age, gender, or anthropometric variables. The patients had significantly higher levels of IL-6, TNF-α, RCP, TBARS, and isoprostanes, and lower levels of SOD than the controls. Twenty-three of the patients were treated with azithromycin, and they had more severe clinical and radiological parameters than those who were not but nevertheless presented significantly lower levels of TNF-α. No differences were observed in the markers of oxidation. CONCLUSION: Inflammation and oxidation biomarkers were increased in patients with CF compared with controls. The use of azithromycin was associated with reduced TNF-α levels and did not influence oxidation parameters.
OBJECTIVE: In addition to their antibiotic effect, macrolides appear to modulate the inflammatory response in cystic fibrosis (CF) and could influence oxidative stress. The objective of this study was to assess oxidation biomarkers and levels of inflammation and to determine whether there is an association between these parameters and the intake of macrolides. MATERIALS AND METHODS: The subjects included in this cross-sectional study were, on the one hand, clinically stable patients with CF and, on the other, healthy controls. The following serum and plasma inflammatory and oxidative stress biomarkers were measured: interleukin-6 (IL-6), reactive C protein (RCP), tumor necrosis alpha (TNF-α), glutathione peroxidase (GPx), total antioxidant capacity (TAC), catalase (CAT), and superoxide dismutase (SOD), together with markers of lipid peroxidation (8-isoprostanes and thiobarbituric acid reactive substances [TBARS]). Clinical, anthropometric, lung function, radiological, and analytical variables (albumin, prealbumin, vitamins, and zinc) were also recorded. RESULTS: We studied 36 adults with CF and 41 controls. No differences were observed in age, gender, or anthropometric variables. The patients had significantly higher levels of IL-6, TNF-α, RCP, TBARS, and isoprostanes, and lower levels of SOD than the controls. Twenty-three of the patients were treated with azithromycin, and they had more severe clinical and radiological parameters than those who were not but nevertheless presented significantly lower levels of TNF-α. No differences were observed in the markers of oxidation. CONCLUSION:Inflammation and oxidation biomarkers were increased in patients with CF compared with controls. The use of azithromycin was associated with reduced TNF-α levels and did not influence oxidation parameters.
Authors: J Roca; J Sanchis; A Agusti-Vidal; F Segarra; D Navajas; R Rodriguez-Roisin; P Casan; S Sans Journal: Bull Eur Physiopathol Respir Date: 1986 May-Jun
Authors: William P Sexauer; Anas Hadeh; Pamela A Ohman-Strickland; Robert L Zanni; Laurie Varlotta; Douglas Holsclaw; Stanley Fiel; Gavin R Graff; Arthur Atlas; Dorothy Bisberg; Denis Hadjiliadis; Suzanne H Michel; Daria Mintz; Rebanta Chakraborty; Bridget Marra; Paula Lomas; Tara Ward; Meagen Sassman; Giovanna C Imbesi; Diane M Kitch; Allison M Mallowe Journal: J Cyst Fibros Date: 2015-01-07 Impact factor: 5.482
Authors: Elizabeth J Reverri; Brian M Morrissey; Carroll E Cross; Francene M Steinberg Journal: Free Radic Biol Med Date: 2014-08-27 Impact factor: 7.376
Authors: Eduardo Garcia-Fuentes; Mora Murri; Lourdes Garrido-Sanchez; Sara Garcia-Serrano; Jose M García-Almeida; Inmaculada Moreno-Santos; Francisco J Tinahones; Manuel Macias-Gonzalez Journal: Obesity (Silver Spring) Date: 2009-10-08 Impact factor: 5.002
Authors: Rachida Legssyer; François Huaux; Jean Lebacq; Monique Delos; Etienne Marbaix; Patrick Lebecque; Dominique Lison; Bob J Scholte; Pierre Wallemacq; Teresinha Leal Journal: Respir Res Date: 2006-10-25
Authors: Adam J Causer; Janis K Shute; Michael H Cummings; Anthony I Shepherd; Mathieu Gruet; Joseph T Costello; Stephen Bailey; Martin Lindley; Clare Pearson; Gary Connett; Mark I Allenby; Mary P Carroll; Thomas Daniels; Zoe L Saynor Journal: Redox Biol Date: 2020-01-23 Impact factor: 11.799